<DOC>
	<DOCNO>NCT01175200</DOCNO>
	<brief_summary>This study establish optimal therapeutic strategy patient coronary artery disease ( CAD ) chronically treat clopidogrel 75 mg/day require co-administration anti-platelet treatment P2Y12 antagonist PPI treatment/prevention GI ulceration .</brief_summary>
	<brief_title>Double Dose Clopidogrel Switch Prasugrel Antagonize Proton Pump Inhibitor Interaction .</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Inclusion Criteria : patient stable Coronary Artery Disease ( &lt; 3 month ) treat clopidogrel ( 75mg/d ) Between 18 75 year age Body Mass Index 18 30 kg/m2 body weight less 60 kg No major bleed accord ISTH definition Subjects sign informed consent document Subjects sign separate pharmacogenomic inform consent document Subjects register French national welfare system Personal family history coagulation bleed disorder Use know inhibitor inducer CYP2C19 CYP3A include grape fruit juice intake Known hypersensitivity lansoprazole , excipients , substitute benzimidazoles , Known hypersensitivity clopidogrel / prasugrel Antiplatelet treatment clopidogrel + aspirin within 7 day inclusion Any formal indication maintain PPI treatment PPI within 15 day inclusion study Active pathology 10 day inclusion Prior history stent thrombosis Prior history Stroke Employee investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>